BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Study highlights potential for targeting macrophages to improve rheumatoid arthritis outcomes September 27, 2024 Coffee consumption reduces risk of migraines, but not other neurological diseases October 20, 2023 New risk score accurately predicts cardiovascular events in women December 5, 2024
Study highlights potential for targeting macrophages to improve rheumatoid arthritis outcomes September 27, 2024